Bibliographic Details
| Title: |
An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes |
| Authors: |
Stuart L. Goldberg, Pierre Fenaux, Michael D. Craig, Emmanuel Gyan, John Lister, Jeannine Kassis, Arnaud Pigneux, Gary J. Schiller, JungAh Jung, E. Jane Leonard, Howard Fingert, Peter Westervelt |
| Source: |
Leukemia Research Reports, Vol 3, Iss 2, Pp 58-61 (2014) |
| Publisher Information: |
Elsevier, 2014. |
| Publication Year: |
2014 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
Aurora A kinase inhibitor, Alisertib, Safety, Acute myeloid leukemia (AML), Myelodysplastic syndrome (MDS), Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: |
Alisertib (MLN8237) is an investigational, oral, selective, Aurora A kinase (AAK) inhibitor. In this phase 2 trial, 57 patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome received alisertib 50 mg BID for 7 days in 21-day cycles. Responses in 6/35 AML patients (17% response rate with an additional 49% stable disease, 34% transfusion independence) included 1 complete response lasting >1 year. No responses were observed in MDS patients. Adverse events >30% included diarrhea, fatigue, nausea, febrile neutropenia, and stomatitis. Results suggest modest activity in AML, supporting further research to better understand how AAK inhibition may induce leukemic cell senescence. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2213-0489 |
| Relation: |
http://www.sciencedirect.com/science/article/pii/S2213048914000144; https://doaj.org/toc/2213-0489 |
| DOI: |
10.1016/j.lrr.2014.06.003 |
| Access URL: |
https://doaj.org/article/a2b9d4218ede4af98ccf08f31191b15f |
| Accession Number: |
edsdoj.2b9d4218ede4af98ccf08f31191b15f |
| Database: |
Directory of Open Access Journals |
